IDT

Integrated DNA Technologies and Aldevron® Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers

Retrieved on: 
Monday, September 18, 2023
Other Manufacturing, Research, Genetics, Clinical Trials, Stem Cells, Manufacturing, Other Health, Biotechnology, Health, Science, GMP, DNA, Electroporation, Drug Master File, QC, PAM, Integrated DNA Technologies, RNP, Multimedia, RNA, Transfection, Chemistry, IDT, Protein, Documentation, RUO, CGMP, DMF, Integration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Fine chemical, Dietary supplement, Vaccine, CRISPR

Leading CRISPR gene editing companies Integrated DNA Technologies and Aldevron inked a new global distribution agreement to expand key CRISPR solutions for cell and gene therapy customers.

Key Points: 
  • Leading CRISPR gene editing companies Integrated DNA Technologies and Aldevron inked a new global distribution agreement to expand key CRISPR solutions for cell and gene therapy customers.
  • A Drug Master File (DMF) is on file with the U.S. Food and Drug Administration to streamline regulatory filings.
  • SpCas9 Nuclease—a wildtype SpCas9 nuclease for use in development work as well as standard cGMP products for clinical studies.
  • A Drug Master File (DMF) is on file with the U.S. Food and Drug Administration to streamline regulatory filings.

Cancer Registry Software Market to grow by USD 82.3 million from 2022-2027, North America to account for 51% of market growth- Technavio

Retrieved on: 
Wednesday, September 13, 2023
Medicine, Prevalence, Segment, Hospital, Investment, Patient, University, International Association, Electronic health record, USD, Government, CDC, IDT, Prostate cancer, Breast, Growth, World Games, Integration, Health care, Cancer, Lung cancer, FREE, Colorectal cancer, IVD, Mortality, Research, IBM, Private, Information technology, OMH, ROW, McKesson Corporation, Breast cancer, Mobile phone, Pharma, Geography

NEW YORK, Sept. 13, 2023 /PRNewswire/ -- The cancer registry software market size is expected to grow by USD 82.3 million from 2022 to 2027.

Key Points: 
  • NEW YORK, Sept. 13, 2023 /PRNewswire/ -- The cancer registry software market size is expected to grow by USD 82.3 million from 2022 to 2027.
  • In addition, the increasing presence of prominent vendors and the use of EHRs in hospitals are driving the growth of the cancer registry software market in North America.
  • The US and Canada are the key markets for cancer registry software in North America.
  • Growth of the market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of cancer registry software market vendors.

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

Retrieved on: 
Thursday, August 24, 2023
DSM-IV codes, Society, Prevalence, Homocystinuria, Burden, ICC, HCU, IDT, Exhibition Hall of the Ministry of Culture, Cystathionine beta synthase, SAN, Therapy, Report of the 1st Annual Symposium on Relaxed Improvisation, Pharmaceutical industry, Metabolism

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Jerusalem, Israel, August 29 – September 1, 2023.

Key Points: 
  • SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Jerusalem, Israel, August 29 – September 1, 2023.
  • The Company and its collaborators will also present analyses on its prospective HCU natural history study, the prevalence of HCU, and the burden of HCU from the patient perspective highlighting the devastating nature of this rare metabolic disease over patients’ lifetimes and underscoring the urgent need for new treatments.
  • In addition, the Company will present data on the clinical burden of HCU and the relationship between total homocysteine (tHcy) and clinical outcomes, which has been recognized as one of the highest ranked posters at SSIEM.
  • Clinical Characterization of Classical Homocystinuria Due to Cystathionine-beta Synthase Deficiency: Results from the ACAPPELLA Study
    Clinical Burden of Classical Homocystinuria in the United States: A Retrospective Analysis of Optum Market Clarity
    Understanding the Burden of Classical Homocystinuria (HCU) from the Patient’s Perspective: A Qualitative Study

Nano Dimension: Another Stellar Q2/2023 and H1/2023 Results

Retrieved on: 
Monday, August 21, 2023
Intellectual property, Research and development, Nano, Marketing, 3D, AME, G&A, EDT, EBITDA, NO, IDT, Acquisition, Investment, Financial result, Annual general meeting, Deep learning, AM, Depreciation, 3D printing, Bookkeeping, Video game, Fine chemical, Commercial property, Retail, Management, Cryptocurrency, Security (finance), Rolling (metalworking), Clothing, Renting

WALTHAM, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or “Nano” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”), today announced financial results for the second quarter ended June 30th, 2023.

Key Points: 
  • Nano Dimension’s momentum continues, and the second quarter and first half of 2023 are no exception.
  • We have the right people, technologies, and products for this business to continue to deliver strong results.
  • I urge shareholders to vote to protect their investment and the significant value creation opportunity that Nano represents and vote FOR the current Nano Board.
  • The Company will host a conference call to discuss these financial results today, August 21st, 2023, at 9:00 a.m. EDT (4:00 p.m. IDT).

Pagaya Schedules 2023 Annual Meeting of Shareholders

Retrieved on: 
Tuesday, August 8, 2023
Construction & Property, Data Analytics, Finance, Artificial Intelligence, Professional Services, Technology, Fintech, Residential Building & Real Estate, Shareholder, IDT, Intelligence, Annual general meeting, Proxy, Internet, Cryptocurrency, Auction

Pagaya Technologies Ltd. (NASDAQ: PGY) (“Pagaya”), a global technology company delivering artificial intelligence infrastructure for the financial ecosystem, today announced that its 2023 Annual Meeting of Shareholders will be held virtually on September 13, 2023, beginning at 9:00 a.m.

Key Points: 
  • Pagaya Technologies Ltd. (NASDAQ: PGY) (“Pagaya”), a global technology company delivering artificial intelligence infrastructure for the financial ecosystem, today announced that its 2023 Annual Meeting of Shareholders will be held virtually on September 13, 2023, beginning at 9:00 a.m.
  • The virtual meeting website will be accessible prior to the meeting start and shareholders can log in by visiting www.virtualshareholdermeeting.com/PGY2023 .
  • Shareholders may view the proxy materials in advance of the meeting by visiting https://investor.pagaya.com/annual-meeting .
  • Shareholders who wish to vote by proxy ahead of the meeting can do so by following the instructions on their proxy, visiting www.ProxyVote.com and using their control number.

Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition

Retrieved on: 
Thursday, July 27, 2023
University, Biochemistry, Senior, Marketing, Integrated DNA Technologies, Danaher, History, Danaher Corporation, Science, IDT, Acquisition, SAN, Engineering, Genomic Medicine Institute, Integration, III, Management, Melamaravakkadu

SAN DIEGO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that William “Trey” Martin, III has assumed the role of Chief Executive Officer (CEO) of Maravai LifeSciences effective July 27, 2023, consistent with the Company’s previously announced CEO succession plan. Carl Hull, Maravai’s co-founder and prior interim CEO, will continue to serve as Maravai’s Executive Chairman of the Board.

Key Points: 
  • SAN DIEGO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that William “Trey” Martin, III has assumed the role of Chief Executive Officer (CEO) of Maravai LifeSciences effective July 27, 2023, consistent with the Company’s previously announced CEO succession plan.
  • Carl Hull, Maravai’s co-founder and prior interim CEO, will continue to serve as Maravai’s Executive Chairman of the Board.
  • “We are thrilled to have Trey step into the role of CEO at Maravai.
  • Since December 2022, Mr. Martin has served as President, Biologics Safety Testing at Maravai.

Pagaya Announces Timing of Second Quarter 2023 Earnings Release

Retrieved on: 
Monday, July 24, 2023
Professional Services, Data Analytics, Technology, Other Technology, Finance, Fintech, Artificial Intelligence, IR, IDT, Flour, Broadcasting, Cryptocurrency

Pagaya Technologies (NASDAQ: PGY) intends to announce its second quarter 2023 earnings on August 10, 2023.

Key Points: 
  • Pagaya Technologies (NASDAQ: PGY) intends to announce its second quarter 2023 earnings on August 10, 2023.
  • A conference call to discuss those earnings will be held on the same day at 5:00 p.m.
  • Details to register for the live webcast presentation and dial-in information will be available on Pagaya’s IR website located at investor.pagaya.com.
  • The webcast replay will be available on the IR website following the conclusion of the event.

Integrated DNA Technologies Launches New Respiratory Virus Panel

Retrieved on: 
Wednesday, July 19, 2023
Technology, Manufacturing, Health, General Health, Health Technology, Other Technology, Research, Other Manufacturing, Infectious Diseases, Genetics, Science, Influenza A virus subtype H1N1, XGen Studios, Respiratory tract infection, Therapy, SARS-CoV-2, Infection, NGS, Integrated DNA Technologies, COVID-19, Season, Multimedia, Doctor of Philosophy, IDT, RSV, R, Integration, Virus, A-DNA, Vaccine

To meet customer demand for a multiplexed, multiple respiratory disease target panel that provides comprehensive genome coverage, Integrated DNA Technologies (IDT) is revealing a new next generation sequencing (NGS) solution, the xGen Respiratory Virus Amplicon Panel .

Key Points: 
  • To meet customer demand for a multiplexed, multiple respiratory disease target panel that provides comprehensive genome coverage, Integrated DNA Technologies (IDT) is revealing a new next generation sequencing (NGS) solution, the xGen Respiratory Virus Amplicon Panel .
  • Leveraging IDT’s well-established NGS amplicon technology, the panel creates super amplicons to reliably distinguish identified and unidentified viral variants of multiple respiratory viruses in a single panel and allows for tracing evolving epidemiological patterns.
  • View the full release here: https://www.businesswire.com/news/home/20230719949441/en/
    Integrated DNA Technologies is revealing a new next generation sequencing (NGS) solution, the xGen™ Respiratory Virus Amplicon Panel, to support researchers as they combat the challenging diseases of today and prepare for the next pathogen of tomorrow.
  • The xGen Respiratory Virus Amplicon Panel is also compatible with IDT Normalase™ technology .

BOSS Money Launches Naira Currency Payout Option for Remittances to Nigeria

Retrieved on: 
Tuesday, July 18, 2023
IDT Corporation, Friends, First City Monument Bank, Central bank, App Store (iOS/iPadOS), Access Bank, Ecobank, First Bank, Stanbic IBTC Holdings, Fidelity Bank, Polaris Bank Limited, IDT, BOSS, United Bank, Zenith Bank, United, Family, NYSE, Union Bank, Financial services, Bank

Newark, NJ, July 18, 2023 (GLOBE NEWSWIRE) -- BOSS Money, the money remittance service of IDT Corporation (NYSE: IDT), today announced the introduction of naira currency remittances for its customers sending cash to friends and family through direct deposit payout at commercial banks throughout Nigeria.

Key Points: 
  • Dollars at Nigeria’s Leading Banks
    Newark, NJ, July 18, 2023 (GLOBE NEWSWIRE) -- BOSS Money, the money remittance service of IDT Corporation (NYSE: IDT), today announced the introduction of naira currency remittances for its customers sending cash to friends and family through direct deposit payout at commercial banks throughout Nigeria.
  • “BOSS Money customers sending money for direct deposit in Nigeria can now choose between the naira and U.S. dollar,” said Alfredo O’Hagan, IDT’s SVP for Consumer Payments.
  • “Our naira direct deposit option enables Nigerians to quickly and securely receive and use the money sent by friends and family in the United States.”
    The new naira payout option supplements BOSS Money’s robust U.S. dollar payout network in Nigeria.
  • BOSS Money now offers remittances from the United States to Nigeria and 46 other countries at over 280,000 cash pick-up locations in addition to mobile money and direct deposit services.

Nano Dimension Announces Record Q1/2023 Results Revenue of $14.97 Million, 43% YoY Growth

Retrieved on: 
Thursday, June 29, 2023
Maintenance, Marketing, Electronics, AME, DACH, Research, EDT, Additive, IPC, Stratasys, Ink, EBITDA, IDT, Acquisition, AM, R, Video game

One of the most exciting developments this quarter is the fast adoption of our Deep Learning/AI technology, developed by our DeepCube division.

Key Points: 
  • One of the most exciting developments this quarter is the fast adoption of our Deep Learning/AI technology, developed by our DeepCube division.
  • It is now effectively installed in our newer models of machines, advancing industrial inspection, print quality optimization, process optimization, and monitoring and maintenance of machines.
  • Please request the “Nano Dimension NNDM call” when prompted by the conference call operator.
  • For those unable to participate in the conference call, there will be a replay available from a link on Nano Dimension’s website at http://investors.nano-di.com/events-and-presentations.